Immunotherapy Advances in RRMM: An Educational Journey

Access Activity

Overview / Abstract:

Multiple myeloma has become the most common hematologic malignancy in the United States adult population with over 120,000 people living with the disease. Despite new and more effective treatments, multiple myeloma, unfortunately, remains largely incurable with relapse and disease progression still common.

Dr. Ola Landgren Chief of the Myeloma Service at Memorial Sloan-Kettering Cancer Center and professor of medicine at Cornell Medical College discusses advances in the field of immunotherapy for relapsed refractory multiple myeloma (RRMM). He discusses different treatment modalities and their unique strengths and limitations which have shown high antimyeloma activity that may address a critical unmet need in heavily pretreated and refractory patients. Dr. Landgren indicates that future studies will help identify optimal combinations and sequencing of different immunotherapies


Jul 30, 2021


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

1.00 Credit hrs.



Presenters / Authors / Faculty

C. Ola Landgren, MD, PhD
Chief, Myeloma Service
Memorial Sloan-Kettering Cancer Center (MSKCC)
New York, New York

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from bluebird bio, Legend Biotech and Sanofi Genzyme.

Keywords / Search Terms

Annenberg Center for Health Sciences at Eisenhower Multiple Myeloma Myeloma Relapsed Refractory Multiple Myeloma Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map